Webinar: Optimizing Dosing for Radiopharmaceutical Therapies Webinar – Speaker Biographies
Click here to learn more about the Optimizing Dosing for Radiopharmaceutical Therapies Webinar and explore the agenda.
Panel Discussion:
Head of Nuclear Oncology Physics and Radiation Biophysics
RayzeBio, a Bristol Myers Squibb Company
Eileen Sneeden is Head of Nuclear Oncology Physics and Radiation Biophysics at RayzeBio, a Bristol Myers Squibb Company. with an innovation-leading position in actinium-based radiopharmaceutical therapeutics (RPTs) including RYZ101, a Phase 3 investigational, targeted RPT in a global Phase 3 study for treating patients with NETs. Previously an accelerator instrumentationalist and radiation biophysicist (US Department of Energy/Stanford Synchrotron scientist), Eileen retooled in 2015 at UCLA Medical Physics, shifting her focus into a passion to do her part in advancing standard of care after unexpectedly losing someone dear to a disease. A believer in a patient-first approach, Eileen joined RayzeBio in 2021 within 60 hours of the initial recruiter call, recognizing immediately the potential impact of targeted alpha therapy in the clinic. She remains passionate for patients (and their families) to win!
Vicki Jardine
VP Global Clinical Development
Ratio Therapeutics
Vicki Jardine, M.D., Ph.D., is Vice President, Global Clinical Development at Ratio Therapeutics, with over 16 years of experience leading oncology drug development, from first-in-human through to pivotal trials. She has particular interest on the development of innovative radiopharmaceutical therapies. She currently oversees clinical development for radiopharmaceutical programs at Ratio, building on prior leadership roles at ARTBIO and Bayer where she led early clinical development for multiple targeted alpha radiotherapeutic agents. Vicki completed her medical doctorate, bachelors degree in neuroscience, and Ph.D. in radiology at the University of Cambridge, UK. She has contributed to cross-academia/industry work focused on radiopharmaceutical therapy development.
Vice President, Global Head PK Science – Oncology
Novartis
Dr. Shefali Kakar is an internationally recognized pharmaceutical executive currently serving as Vice President and Global Head of Oncology Pharmacokinetics (PK) Sciences at Novartis. In her current executive leadership role, Dr. Kakar directs the pharmacokinetics, drug metabolism, and clinical pharmacology strategies for the entire Novartis oncology portfolio.
She has over 20 years of drug discovery expertise and has contributed to the development of more than 40 pharmaceutical products.
Professor
Mayo Clinic Arizona
Phillip Kuo M.D., PhD. graduated from Harvard University, earned an MD/PhD from University of Virginia, and then trained in Internal Medicine at UCLA and Nuclear Medicine and Radiology at Yale. He is Professor in the Department of Radiology at Mayo Clinic Arizona. He provides expertise in the design, conduct, analysis, and reporting of phase 1-3 clinical trials. He has more than 160 peer-reviewed publications and has served as PI or co-PI on numerous NIH grants and industry-sponsored clinical trials.
Mira A. Patel, MD, MS
Senior Director, Oncology R&D Strategy
AstraZeneca
Mira Patel is a Medical Director in Early Global Development Oncology at AstraZeneca. She is a Radiation Oncologist and physician-scientist whose work over the last 15 years spans the translation of radiobiology and tumor immunology into portfolio development strategy. With her Radiation Oncology training, she brings a perspective grounded in the fundamentals of radiotherapeutic dose optimization. At AstraZeneca, she has led RPT clinical development programs and directed the design and enterprise-wide deployment of AI-enabled clinical development platforms. In her current role in Oncology R&D Strategy, she focuses on how emerging evidence should shape portfolio-level development decisions across emerging modalities. Her particular interest is in building fit-for-purpose development frameworks for modalities that existing paradigms do not serve well.
Mira completed her undergraduate training at Cornell University, received her medical degree from Johns Hopkins University School of Medicine, trained in Radiation Oncology at Memorial Sloan Kettering Cancer Center, and completed postdoctoral work in tumor immunology at The Rockefeller University.
Dan Pryma, MD
Vice President – Global Clinical Development
Eli Lilly & Co
Dan Pryma, MD is Vice President, Global Clinical Development at Eli Lilly & Co overseeing clinical development of the radioligand therapy portfolio. He is a nuclear medicine physician and was previously the Gerd Muehllehner Professor of Radiology and Chief of the Division of Nuclear Medicine Imaging and Therapy at the Perelman School of Medicine as well as the Associate Director for Clinical Research of the Abramson Cancer Center at the University of Pennsylvania.